A detailed history of Sherbrooke Park Advisers LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 17,396 shares of NTLA stock, worth $140,385. This represents 0.06% of its overall portfolio holdings.

Number of Shares
17,396
Previous 22,515 22.74%
Holding current value
$140,385
Previous $263 Million 52.89%
% of portfolio
0.06%
Previous 0.08%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

SELL
$7.11 - $12.8 $36,396 - $65,523
-5,119 Reduced 22.74%
17,396 $124 Million
Q4 2024

Feb 14, 2025

BUY
$11.41 - $21.09 $256,896 - $474,841
22,515 New
22,515 $263 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $613M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.